



# ISLHD CLINICAL TRIALS

## *Shoalhaven Cancer Care Centre*

May 2024

### **ISLHD CANCER CLINICAL TRIALS UNIT**

**Shoalhaven Cancer Care  
Centre**

**Shoalhaven District  
Memorial Hospital**

**Corner of Scenic Drive &  
North Street  
Nowra NSW 2541**

**Ph: 02 4253 4384**

**Fax: 02 4222 5085**

**Email: ISLHD-  
CancerClinicalTrials@health.  
nsw.gov.au**

The Illawarra Shoalhaven Local Health District (ISLHD) Cancer Clinical Trials Unit has a specialist team of doctors, nurses, radiation therapists and allied health professionals supporting a comprehensive suite of clinical trials for our local community. We are based at Wollongong and Shoalhaven District Memorial Hospitals in the Illawarra Cancer Care Centre and Shoalhaven Cancer Care Centre.

Clinical trials contribute to evidence based practice, knowledge development and improved patient care. They provide our patients the opportunity to access novel and potentially efficacious treatment for their cancer close to home.

We currently have trials open for patients with:

- Colorectal cancer
- Gynaecological neoplasms
- Skin cancer
- Multiple Myeloma





### **REFERRAL OR CONSULTATION**

To discuss your patient with an ISLHD Trials Clinician, please phone the Shoalhaven Cancer Care Centre on  
02 4428 7400

# ISLHD Clinical Trials

## \*\*CURRENTLY OPEN FOR RECRUITMENT\*\*

Scan the QR Code for more information including eligibility criteria

<b>GI/Biliary</b>	<b>OXTOX:</b> Can oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study.	Prof Chantrill <a href="#">*Satellite site</a>	
<b>Gynae</b>	<b>PARAGON-II:</b> Phase II basket study of an ARomatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms. <b>**Cohorts A, B, D, E, F (limited spots) only**</b>	Dr Kasherman <a href="#">*Satellite site</a>	
<b>Skin</b>	<b>CPOST:</b> A randomised, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.	A/Prof Brungs <a href="#">*Satellite site</a>	
<b>Multiple Myeloma</b>	<b>CA057-001:</b> A Phase 3, Two-Stage, Randomized, Multi-center, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)	Dr Parmar <a href="#">*Satellite site</a>	

For further information regarding these trials at the Shoalhaven Cancer Care Centre you may also contact the trial coordinators as listed or email [ISLHD-SCCC-CancerClinicalTrials@health.nsw.gov.au](mailto:ISLHD-SCCC-CancerClinicalTrials@health.nsw.gov.au)

<b>Trial Coordinator</b>	<b>Availability</b>	<b>Contact details</b>
Kyrie Rodgers	Mon-Thurs	02 4428 7516
Rachael Dunster	Tues, Thurs, Fri	02 4429 1676
Jamie Tomlinson [maternity leave from Nov 2023]	Wed-Fri	02 4429 1676